A Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of the Tramadol Orally Disintegrating Tablet for the Treatment of Premature Ejaculation Within Less Than 2 Minutes

详细信息	查看全文 | 推荐本文 |

• 作者：David Bar-Or^a ; ^b ; ^c ; ^{dbaror@ampiopharma.com} ; Kristin M. Salottolo^a ; ^b ; ^c ; Alessandro Orlando^a ; ^b ; James V. Winkler^c ; for the Tramadol ODT Study Group¹
• 关键词：Premature ejaculation ; Randomized controlled trial ; Placebo ; Intravaginal ejaculation latency time ; Premature ejaculation profile questionnaire ; Tramadol
• 刊名：European Urology
• 出版年：2012
• 期刊代码：289_03022838
• 类别：med
• 出版时间：April, 2012
• 卷：61
• 期：4
• 页码：736-743
• 文件大小：762 K

摘要

Background

Premature ejaculation (PE) is a widely observed male sexual dysfunction with a major impact on quality of life for many men and their sexual partners.

Objective

To assess the safety of tramadol orally disintegrating tablet (ODT) (Zertane) and its efficacy in prolonging intravaginal ejaculation latency time (IELT) and improving Premature Ejaculation Profile (PEP) scores.

Design, setting, and participants

We conducted an integrated analysis of two identical 12-wk randomized double-blind, placebo-controlled phase 3 trials across 62 sites in Europe. Healthy men 18-65 yr of age with a history of lifelong PE according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision, and an IELT 鈮?20 s were included. There were 604 intent-to-treat subjects included in the analysis.

Intervention

Subjects were randomized to receive 1:1:1 placebo (n = 200), 62 mg tramadol ODT (n = 206), or 89 mg tramadol ODT (n = 198).

Measurements

We measured overall change and fold increase in median IELT and the mean change in all four measures of the PEP. Differences across treatment groups were analyzed using Wilcoxon rank-sum tests, analysis of variance, and chi-square analyses.

Results and limitations

Tramadol ODT resulted in significant increases in median IELT compared with placebo; increases were 0.6 min (1.6 fold), 1.2 min (2.4 fold), and 1.5 min (2.5 fold) for placebo, 62 mg tramadol ODT, and 89 mg tramadol ODT, respectively (p < 0.001 for all comparisons). Men saw significantly greater improvement in all four measures of the PEP in both doses compared with placebo (p < 0.05 for all comparisons). Tramadol ODT was well tolerated; study discontinuation occurred in 0%, 1.0%, and 1.6%of subjects in placebo, 62 mg, and 89 mg tramadol ODT groups, respectively. Limitations include study inclusion for men with IELT up to 120 s.

Conclusions

On-demand 62 mg tramadol ODT is an effective treatment for PE in a low and safe therapeutic dose and provides a new option for managing mild to severe PE.

Trial registration

ClinicalTrials.gov identifiers and ; .